新型CFTR增效剂在获得性CFTR功能障碍的慢阻肺雪貂模型中的评估
该研究在香烟烟雾暴露6个月诱导的慢阻肺伴慢性支气管炎雪貂模型中,评估获得性CFTR功能障碍及新型CFTR增效剂GLPG2196的药理逆转作用。结果显示烟雾暴露导致CFTR功能障碍、黏液黏度增加、黏液纤毛清除延迟、气道壁增厚及上皮肥大;GLPG2196治疗1个月可逆转CFTR功能障碍、降低黏液黏度增加黏液转运并减轻支气管壁增厚和上皮肥大。结论提示药理逆转获得性CFTR功能障碍对慢阻肺雪貂模型的慢性支气管炎病理特征有益。
要点
- 香烟烟雾暴露6个月可诱导雪貂出现获得性CFTR功能障碍及慢性支气管炎病理特征。
- GLPG2196可逆转CFTR功能障碍并改善黏液纤毛清除功能。
- 药理逆转CFTR功能障碍可减轻气道壁增厚和上皮肥大。
核心结论
- 药理逆转获得性CFTR功能障碍对慢阻肺雪貂模型的慢性支气管炎病理特征有益。
研究设计与样本
- 雪貂经6个月香烟烟雾暴露诱导慢阻肺和慢性支气管炎,随后每日一次肠内给予GLPG2196治疗1个月。
- 采用电生理离子转运和CFTR功能测量、一微米光学相干断层成像和粒子追踪微流变学评估黏液纤毛功能、微计算机断层成像、组织病理学分析及CFTR蛋白和mRNA表达定量进行评估。
主要发现
- 香烟烟雾暴露后雪貂出现CFTR功能障碍、黏液黏度增加、黏液纤毛清除延迟、气道壁增厚和气道上皮肥大。
- 在慢阻肺雪貂中,GLPG2196治疗逆转CFTR功能障碍,通过降低黏液黏度增加黏液转运,并减少支气管壁增厚和气道上皮肥大。
临床怎么用
- 在慢阻肺伴慢性支气管炎患者中,获得性CFTR功能障碍可能是潜在治疗靶点,但尚需临床研究验证。
局限性
- 研究为雪貂动物模型,结果向人类慢阻肺患者的转化需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: The majority of chronic obstructive pulmonary disease (COPD) patients have chronic bronchitis, for which specific therapies are unavailable. Acquired cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction is observed in chronic bronchitis, but has not been proven in a controlled animal model with airway disease. Furthermore, the potential of CFTR as a therapeutic target has not been tested in vivo, given limitations to rodent models of COPD. Ferrets exhibit cystic fibrosis-related lung pathology when CFTR is absent and COPD with bronchitis following cigarette smoke exposure. OBJECTIVES: To evaluate CFTR dysfunction induced by smoking and test its pharmacological reversal by a novel CFTR potentiator, GLPG2196, in a ferret model of COPD with chronic bronchitis. METHODS: Ferrets were exposed for 6 months to cigarette smoke to induce COPD and chronic bronchitis and then treated with enteral GLPG2196 once daily for 1 month. Electrophysiological measurements of ion transport and CFTR function, assessment of mucociliary function by one-micron optical coherence tomography imaging and particle-tracking microrheology, microcomputed tomography imaging, histopathological analysis and quantification of CFTR protein and mRNA expression were used to evaluate mechanistic and pathophysiological changes. MEASUREMENTS AND MAIN RESULTS: Following cigarette smoke exposure, ferrets exhibited CFTR dysfunction, increased mucus viscosity, delayed mucociliary clearance, airway wall thickening and airway epithelial hypertrophy. In COPD ferrets, GLPG2196 treatment reversed CFTR dysfunction, increased mucus transport by decreasing mucus viscosity, and reduced bronchial wall thickening and airway epithelial hypertrophy. CONCLUSIONS: The pharmacologic reversal of acquired CFTR dysfunction is beneficial against pathological features of chronic bronchitis in a COPD ferret model.
引用
- Kaza N, Lin VY, Stanford D, et al. Evaluation of a novel CFTR potentiator in COPD ferrets with acquired CFTR dysfunction. Eur Respir J. 2022. PMID: 34916262. doi:10.1183/13993003.01581-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。